Nanotools Bioscience specializes in innovative nanotechnology-based solutions aimed at enhancing drug discovery processes. Their primary technology, GraMOS, enables all-optical assays that allow for dynamic stimulation of live cells during high-throughput screening. This approach addresses a significant challenge in drug discovery, where traditional assays often fail to replicate the dynamic nature of cellular responses in vivo. By utilizing specialized microplates with built-in optical stimulation capabilities, Nanotools Bioscience facilitates the identification of use-dependent drugs, thereby improving the predictive value of screening assays and reducing the likelihood of false positives and negatives.

The company's focus on creating a more efficient drug discovery paradigm is encapsulated in their commitment to the "fail fast, fail cheap" philosophy. By ensuring that in vitro conditions closely mimic in vivo environments, their technology allows for real-time monitoring of cellular responses to drug stimuli. This not only accelerates the identification of effective therapeutic targets but also streamlines the overall drug development process, making it faster and more cost-effective. Through their advanced optical control technologies, Nanotools Bioscience aims to transform the landscape of drug discovery, ultimately leading to safer and more effective treatments for patients.

United States

Nanotools Bioscience is developing specialized nanotechnology-based cell culture microplates with “built-in” optical stimulation capabilities to provide dynamic optical stimulation of genetically intact cells during high-throughput screening drug discovery campaigns.

Nanotools Bioscience

Company Details